Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Biohit Oyj Director's Dealing 2017

Feb 24, 2017

3304_rns_2017-02-24_2ee58795-7a4a-4758-b4cd-d9748a1427fa.html

Director's Dealing

Open in viewer

Opens in your device viewer

Biohit Oyj - Managers' Transactions

Biohit Oyj - Managers' Transactions

Biohit Oyj - Managers' Transactions, February 24, 2017 at 2:45 pm local time
(EET)

Person subject to the notification requirement
Name: Nordström, Niklas
Position: Chief Financial Officer


Initial Notification
Reference number: 74370089ATTSNBXJVT29_20170224110530_7


Issuer
Name: Biohit Oyj
LEI: 74370089ATTSNBXJVT29


Transaction details
Transaction date: 2017-02-23
Venue: NASDAQ HELSINKI LTD (XHEL)
Nature of the transaction: Exercise (Rights, Put and Call Options)
Further details:
Linked to stock option programme

Instrument: Financial Instrument Linked to a Share or a Debt
Instrument
ISIN: FI4000219324

Volume: 5204
Unit price: 3,26240 Euro

Aggregated transactions
Volume: 5204
Volume weighted average price: 3.26240 Euro

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
[email protected]
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s
mission is “Innovating for Health” – we produce innovative products and
services to promote research and early diagnosis. Biohit is headquartered in
Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B
share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.
www.biohithealthcare.com